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Purpose:  The  aim  of this  study  was  to evaluate  the  impact  of  the  3D  automated  breast  ultrasound  (3D
ABUS)  when  added  to  full ﬁeld  digital  screening  mammography  (FFDSM),  on  breast  cancer  detection
and  recall  rates  in  asymptomatic  women  with  dense  breasts  examined  in  a  high-volume  breast  cancer
screening  mammography  center.
Methods  and  material:  1668  asymptomatic  women,  age 40–74 years,  with  heterogeneously  dense
parenchyma  (ACR3)  or extremely  dense  breast  (ACR4)  were  included  in  the  study.  FFDSM  was  performed
using  standard  craniocaudal  (CC)  and  mediolateral  oblique  (MLO)  views  followed  by  anteroposterior  (AP);
lateral (LAT)  and  medial  (MED)  acquisitions  of  3D  ABUS  in  both  breasts.  All mammograms  were  double
read  by  two  dedicated  breast  radiologists.  The  3D  ABUS  was  read  by  the  ﬁrst  radiologist  immediately
after  reading  the  mammograms.  The  second  reader  looked  at the  3D  ABUS  only  if  there  was  a  need  for
consensus  discussion  because  of  unclear  or abnormal  mammograms  or 3D  ABUS.
Results: The  combined  FFDSM  and  3D  ABUS  generated  a total  of  6.6 cancers  per  1000  women  screened
(95%  CI:  3.0,  10.2;  p < 0.001)  compared  with  4.2  cancers  per  1000  women  screened  (95% CI)  for  FFDSM
alone.  The  difference  in  yield  was  an  additional  2.4 detected  cancers  per  1000  women  screened  (95%  CI:
0.6, 4.8;  p  <  0.001).  The  corresponding  recall  rate  per  1000  women  screened  was 13.8 (95%  CI:  9.0,  19.8)
for  FFDSM  alone  and  22.8 for  combined  FFDSM  and  ABUS  (95%  CI: 16.2,  30.0),  yielding  a difference  of an
additional  9.0 recalls  per  1000  women  screened  (95%  CI: 3.0,  15.0;  p = 0.004).
Conclusion:  The  addition  of  3D  ABUS  to FFDSM  in women  with  ACR3  or ACR4  breast  density  signiﬁcantly
improved  invasive  breast  cancer  detection  rate with  an acceptable  recall  increase.
rs.  Pu©  2016  The  Autho
. IntroductionIn the last 25 years, several studies have demonstrated a gradual
ecrease in mortality in women with breast cancer, primarily due
o more widespread implementation of screening mammography
Abbreviations: 3D ABUS, 3 dimensional automated breast ultrasound system;
CR, American College of Radiology; BI-RADS, breast imaging reporting and data
ystem; FFDM, full-ﬁeld digital mammography; FFDSM, full-ﬁeld digital screen-
ng mammography; HHUS, manual handheld ultrasound; CC, craniocaudal; MLO,
ediolateral-oblique; AP, antero-posterior; LAT, lateral; MED, medial; DCIS, duc-
al  carcinoma in situ; IDC, invasive ductal cancer; LCIS, lobular cancer in situ; PAD,
athological anatomical diagnosis.
∗ Corresponding author at: Department of Breast Imaging, Capio S:t Göran Hos-
ital, SE-11281 Stockholm, Sweden.
E-mail address: Brigitte.wilczek@capiostgoran.se (B. Wilczek).
ttp://dx.doi.org/10.1016/j.ejrad.2016.06.004
720-048X/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).blished  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
programs leading to a decline in numbers of late stage cancers [1].
Cause-speciﬁc mortality reductions of up to 45% have been reported
for women  attending breast screening programs [1].
Increased mammographic breast density has been shown to be
an independent determinant of breast cancer and possibly prog-
nosis [2]. Dense breasts are quite common, with approximately
2/3 of all premenopausal women and approximately 30% of elderly
women having 50% or higherbreast density [3]. In clinical practice,
the sensitivity of any form of mammography is limited in women
with mammographically dense breast tissue. In women with more
than 75% breast parenchymal dense tissue, the sensitivity has been
shown to be as low as 48% [3,4]. Moreover, reports have shown the
number of mammographically missed cancers as well as the num-
ber of interval cancers to be higher in parenchymal dense breast
than in fatty breasts. The false–negative mammographic screening
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ate has been shown to ﬂuctuate as much as 10-fold from the lowest
o the highest categories of breast density [4].
Breast lesions initially detected by physical examination or on
ammography are also often examined with HHUS, a technique
hat since long has been used as an adjunctive diagnostic tool
ecause it is not hampered by the limitation of breast density [5].
owever, HHUS is operator dependent, time-consuming and difﬁ-
ult to reproduce [6]. In Caucasian women, no study has so far been
ble to conclusively show that HHUS could replace mammography
s a screening method [7] although in the very recently published
CRIN study, Berg et al. [8] found the cancer detection rate by HHUs
o be similar to FFDM with more calciﬁed DCIS detected by FFDM
nd more likely invasive node negative cancer detected by HHUS.
onetheless, HHUS still has the drawback of yielding more false
ositive ﬁndings.
In contrast to HHUS, 3D automated breast ultrasound system
ABUS) has a standardized acquisition protocol that can be per-
ormed by medical personnel after short training without the need
or highly trained radiologists during the examination. 3D ABUS
cquires large 3D volumes that overlap and can be evaluated mul-
iplanar: coronal, transverse and sagittal.
Contrary to standard HHUS, 3D ultrasound technology can visu-
lize each sectional plane of the saved volume because of its digital
haracter. This practice enables temporal comparison which is a
ey factor in breast cancer screening. It can also depict cancers in
he coronal plane thanks to the retraction sign. Breast cancer often
ppears as a stellate lesion with desmoplastic reaction disrupting
he normal parallel soft tissue plane by producing a contraction of
reast tissue towards the mass. The ﬁnding can be seen on several
lices which makes the perception easier [9]. It must, however, be
orne in mind that the retraction sign is not shown in every cancer.
Because of its capabilities, 3D ABUS enables reproducibility
nd can in essence eliminate the investigator-dependent and non-
tandardized documentation [10]. These are characteristics that
ould make 3D ABUS a very useful addition to the diagnostic breast
creening armamentarium as suggested by Brem et al. [11].
The objective of this study was to evaluate the impact of the 3D
BUS when added to FFDSM on breast cancer detection and recall
ate in asymptomatic women with dense breasts examined in a
igh-volume breast cancer screening mammography center.
. Material and methods
The study was approved by the Regional Ethical Review Board
nd written informed consent was obtained from all patients.
.1. Enrollment of research participants
All women invited for breast cancer service screening mam-
ography between November 1, 2010 and February 3, 2012 were
onsidered for inclusion. Inclusion criteria were ages 40 or older,
symptomatic, ACR3 and ACR4 density on assessment by radiogra-
her in the screening situation. Women  were excluded if they were
urrently pregnant or breastfeeding, had undergone breast surgery
r had a history of cancer diagnosis and/or breast cancer treatment
uring the preceding 12 months.
Health status for all participants was surveyed from study entry
ntil the completion of a 24 month follow-up period. This involved
 routine FFDSM if the determination at study entry was normal or
f the outcome of an abnormal determination was benign.
.2. FFDSMThe equipment used was in all cases either a FFDM Microdose
enographe (Philips Solna, Sweden) or a Senographe DS FFDM (GE
ealthcare, Milwaukee WI,  USA). Examination images included twoadiology 85 (2016) 1554–1563 1555
views, mediolateral oblique (MLO) and craniocaudal (CC) views in
both breasts.
2.3. 3D ABUS
The equipment was provided by U-Systems, Inc. Sunnyvale,
CA USA. Prior to commencement of the study, two radiographers
received speciﬁc training in the operation of the imaging system
after which they educated the remaining radiographers. Before tak-
ing part in the study, all radiologists participating in the trial had
to review minimum 100 teaching cases and attend a one day tuto-
rial session. The 3D ABUS examination was performed immediately
after the FFDSM was  completed. The 3D ABUS was equipped with a
linear broadband transducer 6–14 MGHZ. The original acquisitions
were performed in the transverse plane as HHUS perpendicular to
the chest wall and reconstructed in the sagittal and coronal planes.
Imaging was done from the chest wall to the skin in 2 mm thick
slices covering areas of approximately 15 × 17 × 5 cm.  The depth
mentioned is the maximum obtainable depth.
The 3D ABUS examination was carried out with the patient in
a supine position and the ﬁbroglandular tissue being ﬂattened by
applying gentle compression to the chest wall. The radiographer
held the transducer during the examination and always performed
at least 3 views of each breast: lateral (LAT), anteroposterior (AP)
and medial (MED). The 3D ABUS examination took 15 min  per
patient.
2.4. 3D ABUS image reading
Five dedicated breast radiologists with experience from 2 to 30
years of mammography reading and 2–12 years of breast HHUS
were involved in the interpretation of the images. The 3D ABUS
review protocol stipulated the review of 3D coronal and transverse
views.
The ﬁrst reader interpreted the FFDSM with a reading time of
1–2 min  followed by 5–7 min  reading time for 3D ABUS. The second
reader interpreted the FFDSM blinded to the ﬁrst reader’s assess-
ment. If any of the readers expressed reading concerns, this was
discussed to achieve consensus. In that situation, the second reader
checked the entire 3D ABUS knowing that the ﬁrst reader had a
suspicious ﬁnding either on FFDSM or 3D ABUS images or on both
examinations but without the knowledge of the location. Otherwise
the 3D ABUS examination was  not double read.
2.4.1. Interpretation of 3D ABUS ﬁndings and recalls
The radiologist described the 3D ABUS ﬁndings and, in recall
cases, the ﬁndings of HHUS according to the following parameters:
shape (round, oval, irregular), orientation (parallel, not parallel),
margins (spiculated, microlobulated), angularity (indistinct, cir-
cumscribed), and echogenicity (hyper, iso, hypo). The likelihood
of a ﬁnding being malignant was  reported according to our cur-
rent nationwide praxis using a ﬁve step coding: (1) normal, (2)
benign, (3) probably benign, (4) highly suspicious of malignancy,
(5) malignant.
All women with suspicious ﬁndings on either FFDSM or 3D
ABUS were recalled and subjected to mammography work–up with
complementaryviews and HHUS. The HHUS was performed by an
experienced breast radiologist using an IU22 (Philips medical sys-
tems, Bothell, WA;  USA). Women  who got code 1–2 at the work-up
examination, were verbally informed that their breast examina-
tion did not show any sign of malignancy and that no additional
measures were needed, but that they would be invited to the next
screening examination after the appropriate time interval. At the
time of the study, our National Board of Health and Welfare recom-
mended that women aged 40–49 years should undergo screening
each 18 month, because younger patients often had more rapidly
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• 8 initially recalled for FFDSM but
not recalled after 3D ABUS  are 
counted in the Healthy group
1675 Screened
with FFDSM 
and 3D ABUS
1499 Healthy
7 Ineligible
169 Discussion
78 FFDSM
91 3D ABUS
• 3 Dense tissue
• 2 Artifact
• 4 Scar
• 1 Fibroadenoma
• 1 Cyst
• 1 Dense Tissu e
• 2 Calcificatio n
• 1cyst
11 Women wit 
benign work-up 
findings
15 FFDSM
findings
(3D ABUS normal 
or abnormal)
4 Women with
benign work-up 
findings
23 3D ABUS only
findings (FFDSM
normal)
• 3 Fibroadenoma
• 4 cyst
• 1 Fibroadenosis
• 2 Papilloma
• 1 Intraductal benign 
calcification
• 1 Fibroadenoma
8 Women had 
benign biopsies
12 Women
subjected to
biopsy
11 Women 
subjected to
biopsy
4 Women had
benign biopsies
• 5 Unifocal
• 1 Multifocal (3 tumors)
• 1 Bilateral (1invasive, 1 DCIS)
7 Women with
breast c ancer
(FFDSM positive)
4 Women with
breast c ancer
(FFDSM negative)
• 3 Unifocal
• 1 Imultifocal (2 tumors)
4 Women with
invasive breast 
cancer
6 Women with
invasive breast 
cancer
• 1 Woman had
normal FFDSM 
workup
• 8 FFDSM & 3D 
ABUS tumors
• 2 FFDSM-only
tumors (DCIS)
• 5 3D ABUS-
only tumors
131 Healthy  38 Recall
(2.3 %)
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dFig. 1. Study ﬂow chart. The ﬁgure presents 1675 study particip
rowing cancers [12]. Not being a compulsory decree, it was not
racticed all over the country but the recommendation was  fol-
owed in our county.
Women  with code 3–5 were all subjected to ﬁne-needle biopsy
nd/or core biopsy in accordance with the praxis in our country.
urgically removed tissue was sent for pathological-anatomical
nalysis, and the ﬁnal pathology was obtained for a concluding
onﬁrmation of diagnosis.
. Statistics
Patient characteristics were compared by BI-RADS classiﬁcation
sing the Pearson chi-square test and Student’s t-test for categor-
cal and continuous variables, respectively. For variables with low
xpected cell counts, the Fisher exact test and Wilcoxon test were
sed for categorical and continuous variables, respectively.
Of primary interest was to determine the increase in cancer
etection with 3D ABUS added to FFDSM compared to FFDSM alone.ubjected to breast cancer screening with FFDSM and 3D ABUS.
Sensitivity and speciﬁcity for both FFDSM and FFDSM + ABUS were
computed using 2 × 2 tables, and comparisons between modalities
were drawn using the mid-P exact binomial test for sensitivity and
the McNemar test for speciﬁcity [13,14].
Positive predictive value (PPV) was  calculated for each modal-
ity among women who  were recommended for recall using three
ACR deﬁnitions: (1) the proportion of screen-detected cancers in
all women with a recommendation other than routine screening
(PPV1), (2) the proportion of screen-detected cancers in women
with a recommendation for a biopsy (PPV2), and (3) the propor-
tion of screen-detected cancers in women  with a performed biopsy
(PPV3). Because all biopsies that were recommended were also per-
formed, estimates for PPV2 and PPV3 were identical. Patients who
were lost to follow-up were included in the denominators, yielding
conservative PPV estimates.The 95% conﬁdence intervals around all diagnostic estimates
and p-values were generated using 1000 bootstrap samples. All
analyses were performed using SAS (SAS Institute, Cary, NC).
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1675
Pa s
consented
1668
Cases eligible
23
Recalled by 
FFSDM alone
1645
Not recalled by 
FFDSM alone
15
Recalled by 
FFDSM + 3D ABUS
8
Not Recalled by 
FFDSM + 3D ABUS
7
Women with 
screen detected 
cancers
0
Screen detected 
cancers
4
Women with 
screen 
detected 
cancers
Follow-up 
screening at 18 
or 24 months
23
Recalled by 
3D ABUS only
1622
Not Recalled by 
FFDSM + 3D ABUS
Fig. 2. Outcome of screening with FFDSM alone and screening with FFDSM and 3D ABUS.
Table 1
Patient demographic and clinical characteristics at enrollment.
Characteristic Total N = 1668 ACR density categories P value*
Heterogeneously (ACR3) N= 999 Extremely (ACR4) N = 669
Age (y)
n 1668 999 669 0.022
Mean  (SD) 49.5 (7.9) 49.9 (7.9) 49.0 (7.8)
Median 48.0 48.0 48.0
Range  (min, max) 40, 69 40, 69 40, 69
Age  group
40–49 y 996 (59.7%) 579 (58.0%) 417 (62.3%) 0.183
50–59  y 446 (26.7%) 276 (27.6%) 170 (25.4%)
60–69  y 226 (13.5%) 144 (14.4%) 82 (12.3%)
Hormone replacement therapy
Yes 248 (14.9%) 139 (13.9%) 109 (16.3%) 0.181
No  1420 (85.1%) 860 (86.1%) 560 (83.7%)
History of biopsy
Yes 63 (3.8%) 39 (3.9%) 24 (3.6%) 0.740
No  1605 (96.2%) 960 (96.1%) 645 (96.4%)
History of breast cancer
Yes 4 (0.2%) 4 (0.4%) 0 (0.0%) 0.154**
No 1664 (99.8%) 995 (99.6%) 669 (100.0%)
Family history
Yes 59 (3.5%) 37 (3.7%) 22 (3.3%) 0.653
No  1609 (96.5%) 962 (96.3%) 647 (96.7%)
tegor
ategor
4
4
e
c
m
c
T
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e* P values derived from Student’s t-test and chi-square test for continuous and ca
** P values derived from Wilcoxon text and Fisher’s exact test for continous and c
. Results
.1. Patient characteristics
Fig. 1 presents the study ﬂow. Of the 1675 asymptomatic women
nrolled in the study, 7 women were excluded because of proto-
ol violation. Thus, a total of 1668 women undergoing screening
ammography (FFDSM) were eligible for analysis with 999 (60%)
lassiﬁed as ACR3 and 669 (40%) classiﬁed as ACR4 (Table 1).
he mean age in eligible women classiﬁed as ACR4 was  49.5
ears, on average almost one year older than women  classiﬁed as
CR3. Other demographic and clinical characteristics were similar
etween women in the ACR3 and ACR4 groups. Among the 1668
ligible women, 248 (14.9%) had used either oral contraceptivesical variables, respectively, unless otherwise noted.
ical variables, respectively.
or hormone replacement therapy. Sixty three women (3.8%) had a
history of breast biopsy, 4 (0.2%) had a history of breast cancer, and
59 (3.5%) had a family history of breast cancer.
4.2. Screening performance
Among the 1668 eligible participants, ﬁndings on screening
FFDSM alone called for a recall in 23 women. The addition of 3D
ABUS supported the need for a recall in 15 of these women, and a
recall could be avoided in 8 women (Fig. 2). Of the 1645 women
who were not recalled on the basis of screening FFDSM alone, 23
were recalled on the basis of 3D ABUS only (Fig. 2). A total of 11
women with breast cancer were identiﬁed (Fig. 2, Table 2a). In can-
cer cases where recall recommendation differed, 4 of 4 cases were
1558 B. Wilczek et al. / European Journal of Radiology 85 (2016) 1554–1563
Table 2a
Breast cancer detection by imaging method.
Characteristic Any Detection with FFDSM Detection with 3D ABUS only Total
Number of women with cancer 7 4 11
ACR  density categories, n (%)
Heterogeneously 4 (57.1%) 2 (50.0%) 6 (54.5%)
Extremely 3 (42.9%) 2 (50.0%) 5 (45.5%)
Size  of cancer (mm)
Mean (SD) 22.4 (10.1) 21.8 (12.6) 22.2 (10.4)
Median (Q1, Q3) 20.0 (16.0, 24.0) 17.0 (13.5, 30.0) 20.0 (14.0, 24.0)
Range  (Min, Max) 14, 44 13, 40 13, 44
Histological classiﬁcation, n (%)
Grade I 0 (0.0%) 2 (50.0%) 2 (18.1%)
Grade  II 5 (71.4%) 1 (25.0%) 6 (54.5%)
Grade  III 2 (28.6%) 1 (25.0%) 3 (27.3%)
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pig. 3. Presentation of a unifocal node negative cancer in left breast visible only on 3
n  rightmost image (tranverse plane). No lesion visible on FFDSM (leftmost image)
etected with 3D ABUS and not with FFDSM alone (p = 0.063). Six
ancers with an invasive growth were detected on both FFDSM and
D ABUS and 2 ductal carcinomas in situ (DCIS) were seen only on
FDSM. One woman had cancer in both breasts; in one breast an IDC
as detected on both FFDSM and 3D ABUS and in the other breast
 DCIS was seen only on FFDSM. Five (45.5%) of the 11 women  with
reast cancer had at least one family member with breast cancer.
ne patient was unable to give any information concerning hered-
ty. Findings by imaging method and characteristics of the cancers
ound in eleven women are shown in Tables 2a and 2b. Fig. 3 illus-
rates a unifocal node negative cancer seen on ABUS only.
.3. Cancer detection
The combined read of FFDSM and 3D ABUS generated a total of
.6 cancers per 1000 women screened (95% CI: 3.0, 10.2; p < 0.001)
ompared with 4.2 cancers per 1000 women screened (95% CI) for
FDSM alone (Table 3). The difference in yield was  an additional
.4 detected cancer per 1000 women screened (95% CI: 0.6, 4.8;
 < 0.001), resulting in a relative increase of 57%.
.4. Screening recallsThe recall rate per 1000 women screened was 13.8 (95% CI: 9.0,
9.8) for FFDSM alone and 22.8 for FFDSM combined with 3D ABUS
95% CI: 16.2, 30.0), yielding a difference of an additional 9.0 recalls
er 1000 women screened (95% CI: 3.0, 15.0; p = 0.004). The recallUS. Cancerous lesion indicated by arrow on central image (coronal plane) and circle
rate from the combined FFDSM and 3D ABUS was  2.3% compared
to 2.1% for FFDSM alone in our ordinary screening program in the
year preceding the study.
4.5. Sensitivity and speciﬁcity
The increase in sensitivity at screening for FFDSM and 3D ABUS
versus FFDSM alone was 36.4% (95% CI: 9.1%, 66.7%; p < 0.001), and
when interval cancers were included, the increase in sensitivity was
25.0% (95% CI: 5.6%, 50.0%; p < 0.001). The difference in speciﬁcity
was −0.7% (95% CI: −1.2%, −0.1%; p = 0.018). The increase in biopsy
rate was  7.2 per 1000 women  screened (95% CI: 3.6, 11.4; p < 0.001),
and the increase in surgery rate was  2.4 per 1000 women screened
(95% CI: 0.6, 4.8; p < 0.001). The PPVs for cancers found (PPV1) and
for biopsies recommended and performed (PPV3) were numerically
smaller for FFDSM and 3D ABUS compared to FFDSM alone with
28.9% (11 of 38) versus 30.4% (7 of 23) for PPV1 and 47.8% (11 of 23)
versus 63.6% (7 of 11) for PPV3; although these differences were
not statistically meaningful (p > 0.10 in both cases). Regardless of
the inclusion of interval cancers, the increase in NPV for FFDSM and
3D ABUS versus FFDSM alone was 0.2% (95% CI: 0.1%, 0.5%; p < 0.05).
4.6. Interval cancersIn ﬁve women (0.3%) cancers were detected in the interval
between their scheduled routine screening time-points. All interval
cancers were detected after the patient had felt a palpable breast
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Table 2b
Characteristics of breast tumors detected on both FFDSM and 3D ABUS in 11 women.
Pat Age (years) Side ACR-density Tumor size on
HHUSa (mm)
Tumor size on
FFDSM (mm)
Clinicopathological features Comments
Tumor size on
PAD (mm)
Histo-logical
cancer type
Elston Grade Estrogen
receptor
Progesteron
receptor
Prolife-ration
factor (KI67)
Human
epidermal
growth factor
receptor
1 42 R 3 9.4, 10 0 32 IDC 1 100% 100% >5% Negative First screen,
40 mm
between
tumors
2  40 R 4 6, 6, 5, 6 0 44 IDC 2 80% – 12% Negative First
screen, <10 mm
between
tumors 9, 13,
14, 10
3  67 R 4 11.3 15 14 IDC 2 100% 97% 10% Negative Radio
frequency
therapy preop
4  67 L 3 10 0 20 IDC 3 100% 90% >40% Negative Lobular
growing
pattern,
ductally
invasive
5  61 R 3 25 20 22 IDC 2 90% <5% 30% Positive Bilateral cancer
L  0 25 19 DCIS 2
6  59 R 3 9 9 16 IDC 3 100% 100% 50% Negative Waited 1 year
for op because
of psychiatric
illness
7  59 L 4 19 18 24 IDC 2 80% 20% 50% Negative
8  40 L 3 30, 8, 5 40 85 DCIS 2 95% (on biopsy) 80% 15% Negative First screen,
>10 mm
between
tumors. Preop
chemotherapy
9  56 L 3 10 25 40 IDC 2 45% 90% 15% Negative Fibrotic
unchanged
pattern at
several FFDSM,
1 axillary met
10  47 R 4 14 0 13 IDC 1 90% 30% 14% Negative Skin retraction,
1 axillary met
11  48 L 3 0 12.5 17 DCIS 2 n.a. n.a. n.a. n.a.
9  LCIS
Calc calciﬁcations, met  metastasis, n.a. not applicable, R right breast, L left breast, ACR American College of Radiology, HHUS manual handheld ultrasound, FFDSM full-ﬁeld digital mammography, PAD pathological anatomical
diagnosis, IDC invasive ductal dancer, DCIS ductal cancer in situ, LCIS lobular cancer in situ.
a Tumor size on HHUS was  in all cases concordant with tumor size on 3D ABUS.
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Table 3
Results of asymptomatic women breast cancer screened with FFDSM alone and combined read (FFDSM and 3D ABUS).
Characteristic FFDSM alone Combined read FFDSM
and 3D ABUS
Difference (FFDSM and 3D
ABUS) − FFDSM alone
Number of women recalled 23 38 15
Number of women with screening cancer found 7 11 4
Sensitivity at study entry (%) 63.6 (33.3, 90.9) 100 (−, −) 36.4 (9.1, 66.7)
Sensitivity including interval cancers (%)a 43.8 (20.0, 69.2) 68.8 (43.3, 92.3) 25.0 (5.6, 50.0)
Speciﬁcity (%) 99.0 (98.5, 99.4) 98.4 (97.8, 98.9) −0.7 (−1.2, −0.1)
Cancer detection rate per 1000 women  screened 4.2 (1.2, 7.2) 6.6 (3.0, 10.2) 2.4 (0.6, 4.8)
Recall  rate per 1000 women  screened 13.8 (9.0, 19.8) 22.8 (16.2, 30.0) 9.0 (3.0, 15.0)
Biopsy rate per 1000 women screened 6.6 (3.0, 10.8) 13.8 (8.4, 19.8) 7.2 (3.6, 11.4)
PPV1 (%) 30.4 (12.3, 49.1) 28.9 (14.3, 42.3) −1.5 (−16.1, 12.8)
PPV2 and PPV3 (%)b 63.6 (33.3, 90.0) 47.8 (27.0, 66.7) −15.8 (−37.5, 5.8)
Number of women not recalled 1645 1630 −15
NPV  at screening (%) 99.8 (99.5, 99.9) 100 (−, −) 0.2 (0.1, 0.5)
NPV  including interval cancers (%)a 99.5 (99.1, 99.8) 99.7 (99.4, 99.9) 0.2 (0.1, 0.5)
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rote: numbers in parentheses are 95% conﬁdence intervals.
a Includes interval cancers.
b Because all recommended biopsies were also performed, PPV2 and PPV3 are ide
ump. Three cases were “clear-cut” interval cancers that were not
reviously visible by any method. In retrospect, two of the inter-
al cancers could have been detected earlier. In one instance the
FDSM was misinterpreted as unchanged microcalciﬁcations with
o suspicion of malignancy on three earlier FFDSM. This case was
ne of the 3D ABUS “discussion cases” where the 3D ABUS was
ouble read. At the retrospective review of the patient’s earlier 3D
BUS no suspicious malignant ﬁndings were seen.
The second case had very subtle signs (only seen on one view) on
oth FFDSM and 3D-ABUS that were initially interpreted as benign
Fig. 4). Characteristics of the interval cancers are shown in Table 4.
. Discussion
The aim of our study was to evaluate the additive value of 3D
BUS to FFDSM. The study was not designed to compare neither
FDSM nor HHUS to 3D ABUS. Our ﬁndings clearly show that it is
easible to implement 3D ABUS into a high volume FFDSM center
nd increase the cancer detection rate in women aged 40–74 years,
hile maintaining an acceptable low recall rate well within the
ecommendations of the European guidelines for quality assurance
n breast cancer screening and diagnosis [15]. Our recall rate also
ompares favorably to the reported recall rate of 10.7% in the ACRIN
tudy and the 8.8% in the J-Start study [8,16].
In our study, the addition of 3D ABUS screening in women
ith dense breast tissue at FFDSM demonstrated a cancer detec-
ion rate of 6.6 cancers per 1000 women screened. The improved
ncremental cancer detection rate of 2.4 cancers per 1000 women
creened was comparable to the rates observed in studies of mam-
ography screening supplemented by HHUS in women with dense
reasts, ranging from 1.9 − 5.3 additional cancers per 1000 reported
5,8,17,18]. Adding HHUS has also been shown to increase the
ancer detection rate in women under age 50 with dense breasts
16,19].
The addition of 3D ABUS to FFDSM resulted in an increase in
ensitivity of 36.4% compared to FFDSM alone and 25% when inter-
al cancers were included in the analysis. This ﬁnding is in line
ith other studies reporting that sensitivity increases when adding
BUS. Kelly et al. [20] reported an increase in sensitivity from 40%
or mammography alone to 81% with the addition of ABUS. In a
ecent study comparing FFDM with 3D ABUS to FFDM alone for
ammography-negative cancers, the addition of 3D ABUS caused
 23.9% sensitivity increase [21]. The small loss of speciﬁcity in our
tudy (−0.7%) compares favorably to the −13.4% speciﬁcity loss
eported in the Somoinsight study [11]..
The tumors seen on both examination modalities were larger
than the ones generally found in our screening program. One expla-
nation is that in our standard screening program we also include
women with fatty breasts, where very small tumors are more eas-
ily detected by FFDSM. In accordance with the study by Leong et al.
[22], we saw more DCIS on FFDSM than on ultrasound supporting
the conclusion by Jeh et al. [23] that detection of microcalciﬁca-
tions without a mass provides difﬁculties even with a 3D ABUS
system. Surprisingly, the tumors detected by 3D ABUS only were
not as small as the ones found in a study by Kaplan [17]. However,
in Kaplan’s study tumor size was  measured on HHUS while we  refer
to the histopathological size measured on the surgically removed
specimens.
Tumor stage at diagnosis still appears to signiﬁcantly affect
overall survival in women afﬂicted with breast cancer, even with
today’s modern and more effective treatment methods, as indicated
by a recent large Dutch population-based study [24]. In our study, 2
of the 4 women  with cancers visible on 3D ABUS only had axillary
metastases indicating later stage cancers. This is contrary to the
ﬁndings by Corsetti et al. [19], who  reported a signiﬁcantly higher
proportion of early stage cancers detected by HHUS only as com-
pared to mammography only (65% and 36%, respectively). However,
our ﬁgures have to be interpreted with caution because of the small
numbers.
In our material, we  did not have any lobular invasive cancers but
one ductal malignancy with lobular growth pattern. One  explana-
tion for this could be the small sample size in our study and the fact
that all known palpable lumps were excluded from the trial. Calciﬁ-
cations can lead to misinterpretation and erroneous diagnosis. The
one cancer in our study that was diagnosed as an interval cancer
because of misinterpretation of calciﬁcations on the FFDSM gives
a misinterpretation rate of 20%. This is lower than the 30% missed
cancers caused by misinterpretation of calciﬁcations reported by
Birdwell et al. [25]. However, because of the large difference in
numbers of malignancies between our two studies a comparison
must be interpreted with caution.
Clearly, new diagnostic tools are needed that can help to identify
malignancies also in dense breasts. MRI  with a short pass technique
is promising but not widely available, still somewhat expensive and
involves an intravenous injection of contrast media [26,27].
Another technique with the potential to become a valuable
adjunct to mammography is tomosynthesis. However, adding
tomosynthesis to FFDSM will increase the radiation dose given
to the woman. In comparison, 3D ABUS has the advantage of no
additional radiation but the disadvantage of being a more time-
consuming procedure.
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Table 4
Characteristics of ﬁve patients with interval cancers. All interval tumors were invasive ductal cancers (IDC).
Pat Age (years) Side ACR- density Tumor size at
HHUS (mm)
Tumor size at
FFDSM (mm)
Clinicopathological features Comments
Tumor size on
PAD (mm)
Elston Grade Estrogen
receptor
Progesteron
receptor
Prolife-ration
factor (KI67)
Human
epidermal
growth factor
receptor
1 69 L 3 17, 21 70a 15, 21 (60 with
DCIS)
2 + + 40% Negative 15 months
post-screening.
Suspicious sign
at FFDSM at
last screening
2  47 L 3 20 20b 21 2 + + 30% Negative 10 months
post-screening.
Minimal sign at
FFDSM and
ABUS at last
screening
3  46 R 4 10, 15, 30 35a 55 2 + + 15% Positive 11 months
post-screening
4  53 R 4 10 0 19 (30 with
DCIS)
2 + + 15% Positive 13 months
post-screening,
vascular
invasion 1
axillary
metastasis.
5  47 R 3 7, 30 0 8, 37 3 + + 30% Negative 23 months
post-screening
normal FFDM
and normal
HHUS 1 year
post-screening,
vascular
invasion 2
axillary
metastases
R right breast, L left breast, ACR American College of Radiology, HHUS manual handheld ultrasound, FFDSM full-ﬁeld digital mammography, PAD pathological anatomical diagnosis, DCIS ductal cancer in situ.
a Densities and calciﬁcations.
b Densities.
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In the Oslo Tomosynthesis Screening Trial [28] comprising
2621 eligible subjects, the addition of tomosynthesis to the mam-
ography screening program improved cancer detection by 31% in
omen with dense breasts, but it did also increase the recall rate
y 0.7% (2.1% to 2.8%). Recently, a prospective comparative Italian
ulticenter trial showed that HHUS had better incremental breast
ancer detection than tomosynthesis in mammography negative
ense breasts at similar false-positive recall rate [29].
The setup of our study was similar to the Somoinsight study
y Brem et al. [11] and the reader performance studies by Skaane
t al. [30] and GIGER et al. [21]. In all three studies the ﬁrst reader
ssessed the mammogram and then 3D ABUS. All three studies
oncluded that adding 3D ABUS to mammography improved the
erformance of mammographic interpretation.
One challenge in using 3D ABUS is the time needed to perform
nd examine the images. In our study the examination done by
he radiographer took 15 min  and the radiologist’s interpretation
f 3D ABUS 5–7 min. This interpretation time is longer than the
.9 min  reported in the Somoinsight study [11], but less than the
 min  reported in the study by Skaane et al. [30]. The reason for the
bserved differences may  depend on differences in learning curves,
ndividual radiologic experience and the way protocols and reports
re ﬁlled out.
Our study has some limitations: First, all dedicated breast radiol-
gists involved in the study had to undergo tutorials prior to study
nitiation but even so each one had to familiarize themselves with
his new modality leading to individual learning curves. Another
imitation is that the 3D ABUS was double red only in case of dis-
ussions, while FFSDM was always double red. Also, we did not have
ccess to a computer-aided detection system for 3D ABUS. Such a
ystem could possibly have been of help to reduce reading timeospectively seen on FFDM and 3D ABUS. Cancerous lesion indicated by arrow.
and improve early cancer detection. Further studies in this area are
needed. Second, the number of study participants was relatively
small in the context of breast screening trials. Third, the study was
not designed to detect mortality which prevented us from analysing
a potentially beneﬁcial effect of the enhanced cancer detection.
6. Conclusion
3D-ABUS appears to be a promising adjunct method to FFDSM
programs for women  with dense breasts, and our study shows
that it is possible to well integrate the technique into the program
of a high-volume screening center. Besides increasing the cancer
detection rate, it has the advantage of maintaining an acceptable
recall rate without affecting the radiation dose given to the patient.
Nevertheless, in order to ﬁnd the best strategies and methods to
detect more breast cancers and reduce the number of investigated
benign lesions further studies are needed. Comparative studies
with tomosynthesis and MRI  with a short pass technique including
cost-effectiveness aspects would be of interest. Such studies can
maybe provide us with answers as how to deﬁne which women
would beneﬁt most from which method, and also help to decide
how to best integrate those methods into the screening program of
women with dense breasts.
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